These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3396610)

  • 1. Plasma protein binding of penbutolol in pregnancy.
    Aquirre C; Rodriguez-Sasiain JM; Navajas P; Calvo R
    Eur J Drug Metab Pharmacokinet; 1988; 13(1):23-6. PubMed ID: 3396610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unchanged protein binding of penbutolol in renal insufficiency: a possible role of carbamylation.
    Aguirre C; Calvo R; Rodriguez-Sasiain JM
    Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):31-4. PubMed ID: 8444514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease in penbutolol central response as a cause of changes in its serum protein binding.
    Martínez Jordá R; Aguirre C; Calvo R; Rodríguez-Sasiaín JM; Erill S
    J Pharm Pharmacol; 1990 Mar; 42(3):164-6. PubMed ID: 1974610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein binding studies of furosemide and penbutolol.
    Gottschalk R; Sistovaris N
    Arzneimittelforschung; 1985; 35(6):899-902. PubMed ID: 4026914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characterization of propofol binding to plasma proteins and possible interactions].
    Garrido MJ; Jiménez RM; Rodríguez-Sasiaín JM; Aguirre C; Aguilera L; Calvo R
    Rev Esp Anestesiol Reanim; 1994; 41(6):308-12. PubMed ID: 7838996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum protein binding of penbutolol in patients with hepatic cirrhosis.
    Aguirre C; Calvo R; Rodríguez Sasiaín JM
    Int J Clin Pharmacol Ther Toxicol; 1988 Nov; 26(11):566-9. PubMed ID: 3243661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents.
    Aguirre C; Rodríguez-Sasiain JM; Calvo R
    Cancer Chemother Pharmacol; 1994; 34(1):86-8. PubMed ID: 8174208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penbutolol: beta-adrenoceptor interaction and the time course of plasma concentrations explain its prolonged duration of action in man.
    Wellstein A; Palm D
    Eur J Clin Pharmacol; 1985; 29(3):293-300. PubMed ID: 3000796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance.
    Ochs HR; Hajdú P; Greenblatt DJ
    Klin Wochenschr; 1986 Jul; 64(14):636-41. PubMed ID: 3762014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of penbutolol and 4-hydroxypenbutolol in plasma or serum by HPLC.
    Bhamra RK; Flanagan RJ; Holt DW
    Biomed Chromatogr; 1986 Jun; 1(3):140-2. PubMed ID: 3506824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereoselective binding of tertatolol and of 4-hydroxytertatolol to human plasma proteins.
    Bastian G; Urien S; Brée F; Jolliet P; Rocher I; Crambes O; Tillement JP
    Eur J Drug Metab Pharmacokinet; 1992; 17(3):233-6. PubMed ID: 1362702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein.
    Eap CB; Cuendet C; Baumann P
    Clin Pharmacol Ther; 1990 Mar; 47(3):338-46. PubMed ID: 2311335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of serum protein binding of felodipine.
    Valle M; Esteban M; Rodríguez-Sasiaín JM; Calvo R; Aguirre C
    Res Commun Mol Pathol Pharmacol; 1996 Oct; 94(1):73-88. PubMed ID: 8948016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration.
    Urien S; Morin D; Renouard A; Rocher I; Tillement JP
    Eur J Clin Pharmacol; 1988; 34(4):381-5. PubMed ID: 2900145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentration.
    Baruzzi A; Contin M; Perucca E; Albani F; Riva R
    Eur J Clin Pharmacol; 1986; 31(1):85-9. PubMed ID: 3780833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma protein binding of quinine: binding to human serum albumin, alpha 1-acid glycoprotein and plasma from patients with malaria.
    Wanwimolruk S; Denton JR
    J Pharm Pharmacol; 1992 Oct; 44(10):806-11. PubMed ID: 1360505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physico-chemical and anlytical studies of penbutolol.
    Hajdú P; Damm D
    Arzneimittelforschung; 1979; 29(4):602-6. PubMed ID: 582753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein binding of nifedipine.
    Otto J; Lesko LJ
    J Pharm Pharmacol; 1986 May; 38(5):399-400. PubMed ID: 2872322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine.
    Spahn H; Kirch W; Hajdu P; Mutschler E; Ohnhaus EE
    Eur J Clin Pharmacol; 1986; 29(5):555-60. PubMed ID: 3956561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting serum protein binding of cocaine in humans.
    Parker RB; Williams CL; Laizure SC; Lima JJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):605-10. PubMed ID: 7473145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.